AU2019411556B2 - 2-Fluorinated bile acids for the treatment of neurodegenerative diseases - Google Patents
2-Fluorinated bile acids for the treatment of neurodegenerative diseases Download PDFInfo
- Publication number
- AU2019411556B2 AU2019411556B2 AU2019411556A AU2019411556A AU2019411556B2 AU 2019411556 B2 AU2019411556 B2 AU 2019411556B2 AU 2019411556 A AU2019411556 A AU 2019411556A AU 2019411556 A AU2019411556 A AU 2019411556A AU 2019411556 B2 AU2019411556 B2 AU 2019411556B2
- Authority
- AU
- Australia
- Prior art keywords
- compound
- general formula
- dihydroxy
- difluoro
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J11/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J33/00—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J33/002—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
- C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/001—Oxiranes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1820887.6 | 2018-12-20 | ||
| GBGB1820887.6A GB201820887D0 (en) | 2018-12-20 | 2018-12-20 | Compounds |
| PCT/GB2019/053665 WO2020128514A1 (en) | 2018-12-20 | 2019-12-20 | 2-fluorinated bile acids for the treatment of neurodegenerative diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2019411556A1 AU2019411556A1 (en) | 2021-06-10 |
| AU2019411556B2 true AU2019411556B2 (en) | 2025-04-03 |
Family
ID=65364420
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019411556A Active AU2019411556B2 (en) | 2018-12-20 | 2019-12-20 | 2-Fluorinated bile acids for the treatment of neurodegenerative diseases |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20220073557A1 (https=) |
| EP (1) | EP3898645B1 (https=) |
| JP (1) | JP7503063B2 (https=) |
| KR (1) | KR102856276B1 (https=) |
| CN (1) | CN113330020B (https=) |
| AU (1) | AU2019411556B2 (https=) |
| BR (1) | BR112021011189A2 (https=) |
| CA (1) | CA3123333A1 (https=) |
| EA (1) | EA202191521A1 (https=) |
| ES (1) | ES3036094T3 (https=) |
| GB (1) | GB201820887D0 (https=) |
| IL (1) | IL284093B2 (https=) |
| MX (1) | MX2021007551A (https=) |
| SG (1) | SG11202105465WA (https=) |
| WO (1) | WO2020128514A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4486318A4 (en) * | 2022-03-02 | 2026-02-25 | Boyce Thompson Institute For Plant Res Inc | Cysteamides, related therapeutic compositions and associated processes |
| GB202208151D0 (en) | 2022-06-01 | 2022-07-13 | Nzp Uk Ltd | Compounds |
| GB202314563D0 (en) | 2023-09-22 | 2023-11-08 | Nzp Uk Ltd | Compounds |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014036379A2 (en) * | 2012-08-31 | 2014-03-06 | Metselex | Bile acids prevent or abolish progression of parkinson's and related neurodegenerative diseases |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ298567A (en) * | 1994-11-23 | 2000-01-28 | Cocensys Inc | Androstane and pregnane derivatives, pharmaceutical compositions and methods of treatment |
| WO1998005337A1 (en) * | 1996-08-01 | 1998-02-12 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
| FR2934596B1 (fr) * | 2008-07-30 | 2015-04-10 | Trophos | Nouveaux derives de l'oxime de cholest-4-en-3-one, compositions pharmaceutiques les renfermant, et procede de preparation |
| ITMI20121344A1 (it) * | 2012-07-31 | 2014-02-01 | Erregierre Spa | Processo di preparazione di acido ursodesossicolico ad elevata purezza |
| CN103333216A (zh) * | 2013-06-04 | 2013-10-02 | 苏州大学 | 5α-6-酮-胆甾烷类似物及其应用 |
| US20150112089A1 (en) | 2013-10-22 | 2015-04-23 | Metselex, Inc. | Deuterated bile acids |
| US11072630B2 (en) * | 2015-03-10 | 2021-07-27 | Metselex, Inc. | Fluorinated and alkylated bile acids |
| GB201812382D0 (en) * | 2018-07-30 | 2018-09-12 | Nzp Uk Ltd | Compounds |
-
2018
- 2018-12-20 GB GBGB1820887.6A patent/GB201820887D0/en not_active Ceased
-
2019
- 2019-12-20 WO PCT/GB2019/053665 patent/WO2020128514A1/en not_active Ceased
- 2019-12-20 CA CA3123333A patent/CA3123333A1/en active Pending
- 2019-12-20 ES ES19831850T patent/ES3036094T3/es active Active
- 2019-12-20 AU AU2019411556A patent/AU2019411556B2/en active Active
- 2019-12-20 KR KR1020217019166A patent/KR102856276B1/ko active Active
- 2019-12-20 SG SG11202105465WA patent/SG11202105465WA/en unknown
- 2019-12-20 MX MX2021007551A patent/MX2021007551A/es unknown
- 2019-12-20 US US17/415,216 patent/US20220073557A1/en active Pending
- 2019-12-20 EP EP19831850.3A patent/EP3898645B1/en active Active
- 2019-12-20 CN CN201980085276.5A patent/CN113330020B/zh active Active
- 2019-12-20 JP JP2021535715A patent/JP7503063B2/ja active Active
- 2019-12-20 EA EA202191521A patent/EA202191521A1/ru unknown
- 2019-12-20 IL IL284093A patent/IL284093B2/en unknown
- 2019-12-20 BR BR112021011189-1A patent/BR112021011189A2/pt unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014036379A2 (en) * | 2012-08-31 | 2014-03-06 | Metselex | Bile acids prevent or abolish progression of parkinson's and related neurodegenerative diseases |
Non-Patent Citations (3)
| Title |
|---|
| HEATHER MORTIBOYS ET AL: "UDCA exerts beneficial effect on mitochondrial dysfunction in LRRK2-G2019S carriers and in vivo", NEUROLOGY, vol. 85, no. 10, 8 September 2015 (2015-09-08), pages 846 - 852 * |
| HEATHER MORTIBOYS ET AL: "Ursocholanic acid rescues mitochondrial function in common forms of familial Parkinson's disease", BRAIN, vol. 136, no. 10, 1 October 2013 (2013-10-01), pages 3038 - 3050 * |
| S. M. BELL ET AL: "Ursodeoxycholic Acid Improves Mitochondrial Function and Redistributes Drp1 in Fibroblasts from Patients with Either Sporadic or Familial Alzheimer's Disease", JOURNAL OF MOLECULAR BIOLOGY, vol. 430, no.21, 1 October 2018 * |
Also Published As
| Publication number | Publication date |
|---|---|
| IL284093B1 (en) | 2025-03-01 |
| EP3898645C0 (en) | 2025-06-25 |
| AU2019411556A1 (en) | 2021-06-10 |
| WO2020128514A1 (en) | 2020-06-25 |
| IL284093A (en) | 2021-08-31 |
| EP3898645B1 (en) | 2025-06-25 |
| GB201820887D0 (en) | 2019-02-06 |
| KR20210125982A (ko) | 2021-10-19 |
| EP3898645A1 (en) | 2021-10-27 |
| CN113330020A (zh) | 2021-08-31 |
| ES3036094T3 (en) | 2025-09-12 |
| BR112021011189A2 (pt) | 2021-08-31 |
| JP2022514401A (ja) | 2022-02-10 |
| MX2021007551A (es) | 2021-10-13 |
| EA202191521A1 (ru) | 2021-09-10 |
| IL284093B2 (en) | 2025-07-01 |
| CN113330020B (zh) | 2024-04-05 |
| CA3123333A1 (en) | 2020-06-25 |
| US20220073557A1 (en) | 2022-03-10 |
| JP7503063B2 (ja) | 2024-06-19 |
| SG11202105465WA (en) | 2021-06-29 |
| KR102856276B1 (ko) | 2025-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240116952A1 (en) | Kras inhibitor and pharmaceutical uses thereof | |
| EP2638023B1 (en) | Crystalline solids of a metap-2 inhibitor and methods of making and using same | |
| AU2019411556B2 (en) | 2-Fluorinated bile acids for the treatment of neurodegenerative diseases | |
| KR20140025383A (ko) | Ｃ４모노메틸 트리터페노이드 유도체 및 그의 이용 방법 | |
| TW200400837A (en) | Novel formulations of anti-inflammatory androstane derivatives and β 2-adrenoreceptor agonists | |
| JP2022525013A (ja) | Ｈｉｖ療法において有用な化合物 | |
| EP4709710A1 (en) | Ionizable cationic lipids for rna delivery | |
| BRPI0708657A2 (pt) | utilização de pelo menos um composto | |
| JP5731397B2 (ja) | ３，５−セコ−４−ノル−コレスタンの新規オキシム誘導体、それを含む医薬組成物、及びその調製方法 | |
| US20250320246A1 (en) | 3-azasteroid compounds for the treatment of diseases related to mitrochondrial function | |
| WO2021027306A1 (zh) | 双氢青蒿素甾体缀合物及其制备方法和应用 | |
| HK40062202A (en) | 2-fluorinated bile acids for the treatment of neurodegenerative diseases | |
| HK40062202B (en) | 2-fluorinated bile acids for the treatment of neurodegenerative diseases | |
| NL2031175B1 (en) | Dhcr24 inhibitory compounds | |
| CN112218878A (zh) | Ntcp抑制剂 | |
| EA046372B1 (ru) | 2-фторированные желчные кислоты для лечения нейродегенеративных заболеваний | |
| CN117015548A (zh) | 合成的熊果酸衍生物和其使用方法 | |
| CN111620816A (zh) | 螺桨烷类衍生物、其制备方法、药物组合物和用途 | |
| EP4043447B1 (en) | Halogenated tetracyclic triterpene derivative, preparation and application thereof | |
| WO2025062143A1 (en) | 7-difluorinated steroids for use in the treatment of neurological or mitochondrial diseases | |
| WO2023077977A1 (zh) | 秋水仙碱衍生物的制备方法及其用途 | |
| IL316485A (en) | Salt form and crystalline form of a biphenyl compound as an immunomodulator and methods for preparing them | |
| EP2457923A1 (en) | Sterol derivative | |
| HK1189878B (en) | Crystalline solids of a metap-2 inhibitor and methods of making and using same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |